Jubilant DraxImage Signs Term Sheet With Cyclopharm For Exclusive License To Market Technegas In The United States

MONTREAL & SYDNEY--(BUSINESS WIRE)--Jubilant DraxImage Inc. (“DraxImage”) and Cyclopharm Limited (“CYC”) are pleased to announce the signing of a term sheet, subject to satisfactory due diligence and execution of the Definitive Agreement and other necessary approvals, providing DraxImage an exclusive license to market and distribute Technegas in the United States. DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain USFDA approval.

Help employers find you! Check out all the jobs and post your resume.